Responses to Epidermal Growth Factor in Prostate Cancer Cell Lines
Author Information
Author(s): A. MacDonald, F.K Habib
Primary Institution: University Department of Surgery (WGH), Western General Hospital, Edinburgh EH4 2XU, UK
Hypothesis
The study aims to compare the response to epidermal growth factor (EGF) and the expression of the EGF receptor in androgen-sensitive and insensitive prostate cancer cell lines.
Conclusion
The androgen-sensitive LNCaP cells showed a significant response to EGF, while the androgen-insensitive DU145 cells did not.
Supporting Evidence
- DU145 cells showed minimal growth response to EGF, while LNCaP cells had a significant increase in growth.
- EGF binding sites were found to be 10-fold more in DU145 cells compared to LNCaP cells.
- Treatment with Mibolerone did not affect EGF receptor expression in LNCaP cells.
Takeaway
This study looked at how two types of prostate cancer cells react to a growth factor called EGF, finding that one type grows more when exposed to it than the other.
Methodology
The study involved comparing the binding of EGF to two prostate cancer cell lines and measuring their growth responses to EGF treatment.
Limitations
The study primarily focuses on in vitro cell lines, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website